Foley Hoag Advises Client CytImmune on Co-Development Agreement for a New Cancer Nanomedicine with AstraZeneca, UK
January 7, 2013
CytImmune, a Foley Hoag LLP client, recently announced that it has entered into a research collaboration with AstraZeneca, UK (AZ) to create a new cancer nanomedicine. This new nanomedicine would bring together two potentially complementary cancer therapies on CytImmune’s gold nanoparticle delivery platform, seeking to improve the safety and efficacy of both. See “Gold Particles Could Deliver Cancer Drugs,” Technology & Innovations, The Boston Globe, December 24, 2012.
The nanomedicine will bind an AZ proprietary drug to CytImmune’s CYT-6091 nanomedicine platform. CYT-6091 has been successfully tested at the National Cancer Institute, Bethesda, MD in a phase I clinical trial in advanced-stage cancer patients. As seen in that study, the gold nanoparticles migrated to tumors, not to healthy tissue, resulting in a dramatic improvement in the safety of systemically administered TNF formulated as CYT-6091.
The Foley Hoag team representing CytImmune in the Agreement was led by partner Hemmie Chang with support from Michelle Limaj.
About Foley Hoag LLP
Foley Hoag provides innovative, strategic legal services to public, private and government clients across the globe. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and private funds fields, and in cross-border disputes. The diverse backgrounds, perspectives and experiences of our lawyers and staff contribute to the exceptional senior level service we deliver to clients ranging from startups to multinational companies to sovereign states. For more information, visit www.foleyhoag.com or follow @FoleyHoag on Twitter.